drug
SITAGLIPTIN PHOSPHATE
Marketedupdated 5mo agoby Merck Sharp & Dohme LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Type 2 Diabetes
all catalysts(3)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 24, 2026
54 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 24, 2027patentUS 7326708*PED235d
- May 24, 2027patentUS 7326708*PED235d
- May 24, 2027patentUS 7326708*PED235d
- Nov 24, 2026compositionUS 732670854d
- Nov 24, 2026compositionUS 732670854d
- Nov 24, 2026compositionUS 732670854d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that